levodopa
E229731
Levodopa is a cornerstone medication for managing Parkinson’s disease symptoms by replenishing the brain’s depleted dopamine levels.
All labels observed (5)
How this entity was disambiguated
This entity first appeared as the object of triple T2033078 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: levodopa Context triple: [Parkinson's disease, hasTreatment, levodopa]
-
A.
rivastigmine
Rivastigmine is a cholinesterase inhibitor medication used to manage symptoms of mild to moderate dementia, particularly in Alzheimer's and Parkinson's disease.
-
B.
Donepezil
Donepezil is a cholinesterase inhibitor medication primarily used to treat cognitive symptoms of Alzheimer's disease.
-
C.
riluzole
Riluzole is a neuroprotective medication that modestly prolongs survival and slows disease progression in people with amyotrophic lateral sclerosis (ALS).
-
D.
memantine
Memantine is a medication that helps manage symptoms of moderate to severe Alzheimer's disease by modulating glutamate activity in the brain.
-
E.
fampridine
Fampridine is a potassium channel blocker medication primarily used to improve walking in adults with multiple sclerosis.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: levodopa Target entity description: Levodopa is a cornerstone medication for managing Parkinson’s disease symptoms by replenishing the brain’s depleted dopamine levels.
-
A.
rivastigmine
Rivastigmine is a cholinesterase inhibitor medication used to manage symptoms of mild to moderate dementia, particularly in Alzheimer's and Parkinson's disease.
-
B.
Donepezil
Donepezil is a cholinesterase inhibitor medication primarily used to treat cognitive symptoms of Alzheimer's disease.
-
C.
riluzole
Riluzole is a neuroprotective medication that modestly prolongs survival and slows disease progression in people with amyotrophic lateral sclerosis (ALS).
-
D.
memantine
Memantine is a medication that helps manage symptoms of moderate to severe Alzheimer's disease by modulating glutamate activity in the brain.
-
E.
fampridine
Fampridine is a potassium channel blocker medication primarily used to improve walking in adults with multiple sclerosis.
- F. None of above. chosen
Statements (52)
| Predicate | Object |
|---|---|
| instanceOf |
antiparkinsonian agent
ⓘ
dopamine precursor ⓘ medication ⓘ |
| adverseEffect |
confusion
ⓘ
dyskinesia ⓘ hallucinations ⓘ impulse control disorders ⓘ motor fluctuations ⓘ nausea ⓘ orthostatic hypotension ⓘ vomiting ⓘ |
| alsoKnownAs |
L-3,4-dihydroxyphenylalanine
ⓘ
L-dopa ⓘ
linked to:
levodopa
|
| approvedForMedicalUse | 1960s ⓘ |
| belongsToClass | aromatic amino acids ⓘ |
| chemicalFormula | C9H11NO4 ⓘ |
| contraindication | concurrent nonselective MAO inhibitor use ⓘ |
| crosses | blood–brain barrier ⓘ |
| discoveredAs | natural plant product ⓘ |
| drugInteraction |
antipsychotic medications
ⓘ
high-protein meals ⓘ nonselective MAO inhibitors ⓘ |
| foundIn | Mucuna pruriens ⓘ |
| hasRouteOfAdministration | oral ⓘ |
| improves |
bradykinesia in Parkinson's disease
ⓘ
postural instability in Parkinson's disease ⓘ rigidity in Parkinson's disease ⓘ tremor in Parkinson's disease ⓘ |
| indication | management of motor symptoms in Parkinson's disease ⓘ |
| isCornerstoneTherapyFor | Parkinson's disease ⓘ |
| isEnantiomerOf | D-dopa ⓘ |
| isomer | L-enantiomer of dopa ⓘ |
| mechanismOfAction |
converted to dopamine in the brain by aromatic L-amino acid decarboxylase
ⓘ
increases central dopaminergic neurotransmission ⓘ |
| metabolizedBy |
aromatic L-amino acid decarboxylase
ⓘ
catechol-O-methyltransferase ⓘ monoamine oxidase ⓘ |
| oftenCombinedWith |
COMT inhibitors
ⓘ
MAO-B inhibitors ⓘ benserazide ⓘ carbidopa ⓘ entacapone ⓘ |
| precursorOf |
dopamine
ⓘ
epinephrine ⓘ norepinephrine ⓘ |
| pregnancyCategory | varies by jurisdiction ⓘ |
| targetsPathophysiology | dopamine deficiency in the nigrostriatal pathway ⓘ |
| transportedBy | large neutral amino acid transporter ⓘ |
| usedFor |
Parkinson's disease
ⓘ
Parkinsonism ⓘ dopamine-responsive dystonia ⓘ restless legs syndrome ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: levodopa Description of subject: Levodopa is a cornerstone medication for managing Parkinson’s disease symptoms by replenishing the brain’s depleted dopamine levels.
Referenced by (10)
Full triples — surface form annotated when it differs from this entity's canonical label.
linked to: levodopa
linked to: levodopa
linked to: levodopa
linked to: levodopa
linked to: levodopa
subject linked to:
benserazide
linked to: levodopa
linked to: levodopa